About cerus corp. - CERS
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
CERS At a Glance
Cerus Corp.
1220 Concord Avenue
Concord, California 94520
| Phone | 1-925-288-6000 | Revenue | 206.13M | |
| Industry | Medical Specialties | Net Income | -15,627,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 14.347% | |
| Fiscal Year-end | 12 / 2026 | Employees | 275 | |
| View SEC Filings |
CERS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.905 |
| Price to Book Ratio | 6.163 |
| Price to Cash Flow Ratio | 81.17 |
| Enterprise Value to EBITDA | -11.863 |
| Enterprise Value to Sales | 1.977 |
| Total Debt to Enterprise Value | 0.238 |
CERS Efficiency
| Revenue/Employee | 749,574.545 |
| Income Per Employee | -56,825.455 |
| Receivables Turnover | 6.786 |
| Total Asset Turnover | 0.975 |
CERS Liquidity
| Current Ratio | 1.73 |
| Quick Ratio | 1.173 |
| Cash Ratio | 0.822 |
CERS Profitability
| Gross Margin | 53.503 |
| Operating Margin | -17.632 |
| Pretax Margin | -7.414 |
| Net Margin | -7.581 |
| Return on Assets | -7.393 |
| Return on Equity | -25.965 |
| Return on Total Capital | -9.696 |
| Return on Invested Capital | -12.623 |
CERS Capital Structure
| Total Debt to Total Equity | 150.95 |
| Total Debt to Total Capital | 60.151 |
| Total Debt to Total Assets | 43.697 |
| Long-Term Debt to Equity | 78.939 |
| Long-Term Debt to Total Capital | 31.456 |